



RECEIVED

OCT 01 2002

#10

1

PTO/SB/08B (10-01)

TECH CENTER 1600/2000

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

## Complete if Known

Application Number	09/891,138
Filing Date	June 25, 2001
First Named Inventor	Lin, Daniel Chi-Hong, et. al.
Art Unit	1646 1647
Examiner Name	Not yet assigned - NICHOLS
Attorney Docket Number	018781-006210US

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
CN	BA	EP	1 096 009	A1	05/02/2001	Pfizer Limited et al.		<input type="checkbox"/>
	BB	WO	00/22131	A2	04/20/2000	Dominic P. Behan et al.		<input type="checkbox"/>
	BC	WO	00/31258	A2	06/02/2000	Ruoping Chen et al.		<input type="checkbox"/>
	BD	WO	01/25432	A2	04/12/2001	Schering Corporation		<input type="checkbox"/>
CN	BE	WO	01/33221	A1	05/10/2001	SmithKline Beecham Corporation et al		<input type="checkbox"/>
	BF	WO	01/46414	A1	06/28/2001	Banyu Pharmaceutical CO., LTD.		<input type="checkbox"/>
	BG	WO	01/85793	A2	11/15/2001	Pharmacia & Upjohn Company		<input type="checkbox"/>

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CN	BH	STADEL J. et al., "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery" Trends in Pharmacological Sciences, Elsevier Trends Journal, Cambridge, GB, vol. 18, no. 11, pp. 430-437, (November 1, 1997)	

Examiner  
Signature

Julia

Date  
Considered

4/8/2003

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1388300 v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 09/891,138  
Filing Date June 25, 2001  
First Named Inventor Lin, Daniel Chi-Hong  
Group Art Unit 1646 1647  
Examiner Name NICHOLAS  
Attorney Docket Number 018781-0061

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
50	AA	5,871,963	A	Conley, et al.	02-16-1999	
50	AB	5,955,309	A	Ellis, et al.	09-21-1999	
50	AC	6,063,582	A	Conley, et al.	05-16-2000	
50	AD	6,204,017	B1	Behan, et al.	03-20-2001	
50	AE	6,222,029	B1	Edwards, et al.	04-24-2001	

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
50	AF	EPO	WO 96/05302	A1	Takeda Chemical Industries, LTD.	02-22-1996		
	AG	EPO	WO 97/24929	A1	Human Genome Sciences, Inc.	07-17-1997		
	AH	EPO	WO 99/06552	A2	Genset	02-11-1999		
	AI	EPO	WO 00/11166	A1	Millennium Pharmaceuticals, Inc.	03-02-2000		
	AJ	EPO	WO 00/22131	A2	Behan, et al.	04-20-2000		
	AK	EPO	WO 00/28032	A2	Incyte Pharmaceuticals, Inc.	05-18-2000		
	AL	EPO	WO 00/61628	A1	Human Genome Sciences, Inc.	10-19-2000		
	AM	EPO	WO 01/31014	A2	Pharmacia & Upjohn Company	05-03-2001		
	AN	EPO	WO 00/31258	A2	Arena Pharmaceuticals, Inc.	06-02-2000		
	AO	EPO	WO 01/36473	A2	Pharmacia & Upjohn Company	05-25-2001		
50	AP	EPO	EP 1090925	A1	Pfizer Limited	04-11-2001		

Examiner Signature

*G. Mielas*

Date Considered

4/8/2003

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1277930 v1

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of

## Complete if Known

Application Number 09/891,138  
Filing Date June 25, 2001  
First Named Inventor Lin, Daniel Chi-Hong  
Group Art Unit ~~4040~~ **1647**  
Examiner Name **NICHOLS**  
Attorney Docket Number 018781-006210US

TECH CENTER 1600/2900

OCT 12 2001

RECEIVED

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
<b>CS</b>	AQ	EPO	EP 1096009	A1	Pfizer Limited	05-02-2001		
	AR	EPO	EP 0892051	A2	Smithkline Beecham Corporation	01-20-1999		
	AS	EPO	EP 0892051	A3	Smithkline Beecham Corporation	01-20-1999		
	AT	JPO	08-245697		Takeda Chemical Industries, LTD.	09-24-1996		
<b>CS</b>	AU	JPO	11032770	A	Asahi Kasei Kogyo KK	07-24-1997		

Examiner Signature

*G. Michael*

Date Considered

**4/8/2003**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

Patents, Washington, DC 20231  
SF 1277930 v1